NEWS2018-02-06T21:16:53+00:00

Client News

Organogenesis to Sponsor Jan. 30 Webinar, “Chronic Wounds and Biofilms: Advancing Assessment and Treatment,” Featuring Dr. Gregory Schultz

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, will sponsor a January 30 WoundSource webinar, "Chronic Wounds and Biofilms: Advancing Assessment and Treatment" led by Gregory Schultz, PhD, Professor of Obstetrics and Gynecology and Director of [...]

January 24th, 2019|

Organogenesis Holdings Inc. Receives Positive Nasdaq Listing Determination

Class A Common Stock to Resume Trading on Nasdaq Organogenesis Holdings Inc. (the "Company") (Nasdaq: ORGO; ORGOW) today announced that on January 4, 2019, the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that, based on the plan of compliance presented by the Company at its hearing, the Nasdaq Hearings Panel (the "Panel") has granted the Company's request [...]

January 7th, 2019|

Exergen Reduces Hospital Costs by 90%

Exergen Corporation has announced that two new studies from Postgraduate Medical Journal indicate that when used throughout a hospital, Exergen TemporalScanners deliver substantial cost savings while providing accuracy and ease of use, as supported by more than 70 peer-reviewed published studies for all ages and clinical settings. Click here to read the full article.

December 28th, 2018|

Client News

Exergen Reduces Hospital Costs by 90%

Exergen Corporation has announced that two new studies from Postgraduate Medical Journal indicate that when used throughout a hospital, Exergen TemporalScanners deliver substantial cost savings while providing accuracy and ease of use, as supported by more than 70 [...]

December 28th, 2018|